Últimas noticias sobre Biohaven (NYSE:BHVN) Bolsa

Biohaven

Biohaven Ltd is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of life-changing treatments in key therapeutic areas, including immunology, neuroscience, and oncology. Its product pipeline includes Glutamate, Myostatin, Ion channels, Inflammation & Immunology, and Oncology. The company's products target diseases such as neuromuscular and metabolic diseases, antibody-drug conjugates for cancer, obsessive-compulsive disorder, and others.

Biohaven Pharma Hldgs

Biohaven Pharmaceutical

Biohaven Ltd

The world&#8217;s largest exchange-traded fund tracking the Nasdaq 100 index is on track for its worst week of outflows since November 2024, highlighting growing investor unease about the sustainability of the tech sector&#8217;s rebound from <a href="https://www.benzinga.com/topic/tariffs">the tariff-led selloff.</a>
The Invesco QQQ Trust, Series 1 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>) lost $3.97 billion over the first four days of the week, according to TradingView data, with Friday's flows yet to be reported. This marks potentially the worst weekly outflows in six months. 
Notably, this exodus occurs even as the Nasdaq 100 posted a robust weekly performance, soaring over 6%.
The VanEck Semiconductor ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMH#NASDAQ">SMH</a>) suffered outflows for $1.4 billion over the week, the worst since July 2024. 
Similarly, the iShares Semiconductor ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SOXX#NASDAQ">SOXX</a>) recorded $347 million in outflows this week, heading toward its worst weekly outflow since December 2024. This drain comes even as chipmaker stocks surged 11% over the same period, the strongest weekly gains since November 2022. 
Pressure is also being felt at the top of the tech elite: The Roundhill Magnificent Seven ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MAGS#NYSE">MAGS</a>) registered outflows for the second consecutive week.
<h1 class="wp-block-heading">Investors Are Rotating Out Of Tech Into Blue-Chip Stocks</h1>
Instead of an outright exit from risk assets, the flows suggest a sector rotation as investors appear to be moving from tech stocks into more traditional blue-chip names.
The SPDR Dow Jones Industrial Average ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DIA#NYSE">DIA</a>) recorded its largest single-day inflow since August 2020 on Monday, with $1.6 billion of fresh capital. 
By the week&#8217;s end, ETF pulled in $1.53 billion overall, eyeing the strongest weekly inflow in nearly five years.
<h1 class="wp-block-heading">Sector Fund Flows: Winners and Losers</h1>
<ul>
<li>The Communication Services Select Sector SPDR Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLC#NYSE">XLC</a>) gathered $124 million, poised for its third consecutive week of inflows.</li>
<li>The Consumer Staples Select Sector SPDR Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLP#NYSE">XLP</a>) attracted $7 million in new capital, halting a two-week streak of outflows.</li>
<li>The Energy Select Sector SPDR Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLE#NYSE">XLE</a>) extended its painful trend, losing $717 million, marking the sixth consecutive week of outflows.</li>
<li>The Consumer Discretionary Select Sector SPDR Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLY#NYSE">XLY</a>) saw an $84 million influx, posting its second straight week of gains.</li>
<li>The Financial Select Sector SPDR Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLF#NYSE">XLF</a>) experienced significant outflows totaling $666 million.</li>
<li>The Health Care Select Sector SPDR Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLV#NYSE">XLV</a>) registered $40 million in outflows.</li>
<li>The Industrials Select Sector SPDR Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLI#NYSE">XLI</a>) attracted $140 million in fresh money.</li>
<li>The Materials Select Sector SPDR Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLB#NYSE">XLB</a>) gained $52 million in inflows.</li>
<li>The Real Estate Select Sector SPDR Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLRE#NYSE">XLRE</a>) saw $62 million in inflows, reflecting growing interest in defensive sectors.</li>
<li>The Technology Select Sector SPDR Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLK#NYSE">XLK</a>) managed to secure $105 million in inflows despite broader tech weakness.</li>
<li>The Utilities Select Sector SPDR Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLU#NYSE">XLU</a>) posted $230 million in new investments, marking its second straight week of inflows, as investors seek safety in traditionally defensive sectors.</li>
</ul>
Read Now: 
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/analyst-color/25/04/45007990/stay-big-sell-rips-hartnett-doubts-bull-market-without-3-key-catalysts">&#8216;Stay BIG, Sell Rips&#8217;: Hartnett Doubts Bull Market Without 3 Key Catalysts</a></li>
</ul>
Photo: Drozd Irina via Shutterstock

Equities

Large Cap

Sector ETFs

Broad U.S. Equity ETFs

Tech

ETFs

SPDR Dow Jones Industrial Average ETF Trust

MAGS

iShares PHLX SOX Semiconductor Sector Index Fund

SOXX

XLRE

Select Sector SPDR-Consumer Discretionary

QQQ ETF Faces Worst Week Of Outflows Since November As Investors Sell The Tech Rally

Last week, I suggested that you buy bonds instead of stocks. It's the smart play.
Even after the big rally Treasury Secretary Scott Bessent <a href="https://www.benzinga.com/markets/25/04/44942218/bill-ackman-praises-treasury-secretary-scott-bessent-as-steady-hand-ahead-of-world-bank-imf-spring-meetings">managed to spark</a> with his tariff reduction talks last week, you would still be better off collecting the coupon from bonds and in a position to cash in some sharp capital gains if the economy does weaken materially and the Fed is forced to lower rates.
Despite the feel-good talk coming out of D.C., it's highly unlikely that the trade-related volatility is over.
Even if the whole world goes to Washington ready to make a deal, it has traditionally taken more than a year to hammer out the terms. And China is denying any talks are taking place.
In times like these, income and small-cap value investments have performed the best.
Following a trade agreement, implementation usually takes a few years to execute. While there have been some discussions, no one seems to be in a rush to have talks at this point.
The major target of all this madness, China, has made it clear as of this writing that it is not talking to Washington and will not talk to Washington until President Trump and his team dial back their harsh rhetoric.
We are more than overdue for some version of a lost decade in stocks, and the uncertainty surrounding tariffs and global trade might be the starter pistol.
If that happens, collecting yield will be more critical than ever.
If you look at the 1970s and the 2000-2010 time period, owning bonds and preferred stocks worked out much better than owning or trying to trade stocks.
Small-cap value strategies also performed very well from 2000 through 2010, a period when the large-cap indexes returned negative returns.
Of course, we can never predict for certain how the world and markets will play out.
Given the economic uncertainty and elevated valuations after a long period of historical outperformance, a lost decade in stocks appears not only possible but probable.
Which brings us to the big question: What if it does not happen?
How will we fare if we position to profit in a lost decade and, instead, the bull market continues to run higher?
It is far from an impossible scenario.
If we hit the right side of the Trump policy Bell Curve and see a massive reshoring of industry, driving a construction boom along with lower taxes and interest rates, we could see a long-term rally of historic proportions.
Add in AI-driven improvements in technology and healthcare, and it could truly be a renaissance of the economy and market.
Should that happen, a portfolio full of high-yield investments and undervalued stocks with a margin of safety in their balance sheets, credit practices and operational excellence should perform at least as well as the indexes.
There would be a huge credit upgrade as companies saw their cash flows increase and balance sheets become even stronger.
The booming economy would lead to a massive M&amp;A wave, and financially solid smaller companies would be among the targets of choice.
I am well aware that most of you read this not so much for my higher-level thoughts but for stock ideas that might be worth adding to your current portfolio.
With that thought in mind, here are two deep-value small-cap stocks worth your attention.
Laureate Education (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LAUR#NASDAQ">LAUR</a>) is a higher education company that runs a network of private universities, mainly in Mexico and Peru. After years of being spread out all over the globe, they&#8217;ve trimmed things down and focused on where they see the best long-term demand.
Laureate operates in places with young, growing populations and a rising middle class hungry for degrees. Their schools offer a wide range of programs, from business and engineering to health sciences, and they&#8217;re aimed at students who want a solid education without the high costs.
The company allows its universities to operate with a good deal of independence but still provides support in areas such as strategy, marketing, and technology. It&#8217;s a model that helps them keep things running efficiently while still tailoring to local markets. After selling off operations in other regions, Laureate used the cash to clean up its balance sheet and return money to shareholders. Now, they&#8217;re a leaner, more focused business with steady cash flow and solid enrollment trends in places where demand for higher education just keeps growing.
The stock is trading at just 8 times the cash produced by the business, and the company has outstanding fundamentals and a more than adequate margin of safety.
World Kinect Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WKC#NYSE">WKC</a>), formerly known as World Fuel Services, is essentially a global middleman for energy. Based in Miami, the company initially focused mainly on selling fuel to planes, ships and trucks around the world. But over time, it&#8217;s broadened its playbook. These days, World Kinect helps companies not only buy fuel but also manage energy costs, hedge against price swings, and determine how to meet their sustainability targets. Their customers range from airlines and shipping fleets to industrial giants and even government agencies.
The customer base is basically anyone who needs a lot of energy and doesn&#8217;t want to get burned by price spikes or supply headaches.
What&#8217;s interesting is how they&#8217;ve started leaning more into the clean energy and ESG side of things. They&#8217;re now offering services like renewable energy sourcing, carbon offsets, and energy efficiency advice. It&#8217;s still mostly a fuel business at heart, but they&#8217;ve been smart about not getting left behind as more companies go green. They run an asset-light operation that is more about logistics, relationships, and scale than owning refineries or power plants.
The bottom line: it&#8217;s a steady, cash-generating business that&#8217;s finding ways to stay relevant in a world that&#8217;s rethinking how it uses energy.
The company has outstanding fundamentals, a huge margin of safety and trades at less than nine times the cash the business generates. It also pays a sizable dividend of almost 3%.
The combination of high income and small-cap deep value should deliver outstanding returns, regardless of what happens in the markets.
If the markets do go south or sideways for a long time, the combination can help you not only survive but thrive through the turbulence.
<h2 class="wp-block-heading">Protect And Grow Your Wealth As Markets Swing Wildly</h2>
Matt Maley's Inner Circle members received alerts for both bullish and bearish trades last month—critical for income generation when markets move unpredictably. 7-day free trial available. Start Your <a href="https://www.benzinga.com/premium/ideas/7-day-free-trial-matt-maley-inner-circle/?el=ResearchDaily&amp;he={{email}}&amp;adt_ei={{email}}&amp;utm_adType=SponsorAd&amp;utm_ad=RD0428&amp;utm_campaign=7daytrial">Free 7-Day Trial</a> Now.
Editorial content from our Expert contributors is intended to be information for the general public and not individualized investment advice. Editors/contributors are presenting their individual opinions and strategies, which are neither expressly nor impliedly approved or endorsed by Benzinga.
Photo: Shutterstock

Opinion

Trading Ideas

LAUR

Trade Deal Or No, These 2 Stocks Will Outperform

American Airlines Group Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAL#NASDAQ">AAL</a>), Alaska Air Group Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ALK#NYSE">ALK</a>) and Southwest Airlines Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LUV#NYSE">LUV</a>) reported their quarterly results broadly in-line with the tone set by Delta Air Lines Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DAL#NYSE">DAL</a>) and United Airlines Holdings Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UAL#NASDAQ">UAL</a>), according to JPMorgan.
The Airlines Analyst: <a href="https://www.benzinga.com/analyst-stock-ratings/analyst/58485285ee7bf6000154d235/jamie-baker">Analyst Jamie Baker</a> maintained ratings, while cutting price targets.
<ul>
<li>American Airlines: Overweight, price target reduced from $26 to $19</li>
<li>Alaska Air Group: Overweight, price target cut from $89 to $73</li>
<li>Southwest Airlines: Underweight, price target trimmed from $30 to $23</li>
</ul>
"Low-end domestic demand is under significant pressure, premium and international remain the bright spots for now, and loyalty returns continue to help cushion the aggregate impact to earnings," Baker said in a note.
Check out <a href="https://www.benzinga.com/analyst-stock-ratings">other analyst stock ratings</a>.
American: The company reported adjusted loss of 59 cents per share, slightly better than consensus of 69 cents per share, the analyst stated. "Passenger revenue was roughly flat, on capacity down 1pt YoY," he added. While American Airlines continue to make progress in recapturing its historical share of indirect revenue by yearend, its margin performance has been flat, Baker said.
Alaska Air Group: The company's adjusted loss came in at 77 cents per share, worse than its January guidance of between 70 and 50 cents per share, the analyst stated. "Management cited a 3pt top-line disruption from demand softness during the quarter, which (all things being equal) would have placed the company comfortably ahead of its guidance," he wrote.
Southwest: The company reported an adjusted loss of 13 cents per share. That&#8217;s better than the consensus of 18 cents per share. Total EBIT minus cost of initiatives implies an EBIT loss of $100 million — $447 million worse than in 2024, Baker said.
Price Action: At the time of publication on Friday, shares of:
<ul>
<li>American Airlines had risen by 0.30% to $9.64</li>
<li>Alaska Air had risen by 1.13% to $41.98</li>
<li>Southwest Airlines had declined by 0.95% to $26.19</li>
</ul>
Read More: 
<ul>
<li><a href="https://in.benzinga.com/25/04/44982328/american-airlines-flies-into-uncertainty-q1-revenue-miss-2025-outlook-pulled-but-debt-plan-on-track">American Airlines Flies Into Uncertainty: Q1 Revenue Miss, 2025 Outlook Pulled, But Debt Plan On Track</a></li>
</ul>
Image: Shutterstock

Analyst Color

Earnings

Price Target

Reiteration

Analyst Ratings

Airlines Face 'Significant Pressure': Analysts Adjust Expectations After Q1 Results

News

Hedge Funds

General

CORRECTION: Galloway Capital Partners Says In Letter To WW International "Weight Watchers is not insolvent and in no way should pursue a Chapter 11 filing. In the event this occurs, we intend to pursue such remedies including the formation of an Equity Committee to protect the value and rights of the equity holders."

WIIM

NVAX

Novavax shares are trading lower following a WSJ report indicating the FDA asked the company to complete a new trial for its Covid-19 vaccine.

<a href="https://www.wsj.com/health/healthcare/novavax-covid-19-vaccine-clinical-trial-fda-de5d3bb3" title="https://www.wsj.com/health/healthcare/novavax-covid-19-vaccine-clinical-trial-fda-de5d3bb3">https://www.wsj.com/health/healthcare/novavax-covid-19-vaccine-clinical-trial-fda-de5d3bb3</a>

Biotech

"FDA Asks Vaccine Maker To Complete New Clinical Trial For Delayed Covid-19 Shot; A New Randomized Study Could Cost Novavax Tens Of Millions Of Dollars, Vaccine Experts Say" - WSJ

BofA Securities analyst Lorraine Hutchinson reiterated a <a target="_blank" href="https://www.benzinga.com/quote/NKE/analyst-ratings" rel="noreferrer noopener">Buy rating</a> on the shares of Nike Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NKE#NYSE">NKE</a>) on Friday and lowered the price forecast from $90.00 to $80.00.
Nike shares have lagged behind the S&amp;P 500 since the April 2 tariff news, falling 12% compared to the index's 5% decline.
Despite this, analysts believe the current tariff exposure remains controllable, and reduced consumer interest in American labels within China has already been factored into the stock.
Also Read: <a target="_blank" href="https://www.benzinga.com/analyst-ratings/analyst-color/25/04/45020318/what-is-the-tariff-risk-for-procter-gamble-analyst-calculates-trims-outlook" rel="noreferrer noopener">What Is The Tariff Risk For Procter &amp; Gamble? Analyst Calculates, Trims Outlook</a>
The price forecast cut reflects a lower F2027 P/E multiple of 27x versus 30x previously due to overall market valuation shifts.
The analyst expects that inventory streamlining through the first half of FY26 will position Nike to accelerate product innovation and eventually boost revenue growth.
Nike maintains a well-spread manufacturing base, with its footwear production split mainly among Vietnam (50%), Indonesia (27%), and China (18%). Apparel manufacturing follows a similar pattern, followed by Vietnam at 28%, China at 16%, and Cambodia at 15%.
Notably, most goods produced in China are sold domestically, minimizing U.S.-bound exports. If 5% of Nike's U.S. imports face a 145% tariff and the rest of the world sees a 10% rate, the average global tariff would settle around 16.75%.
In this scenario, margins would compress by approximately 110 basis points if no countermeasures are taken. However, Nike could neutralize the impact with a modest 2% global price increase.
Should tariffs revert to those proposed on "Liberation Day," the blended rate could jump to 45%, potentially trimming margins by 300 basis points. The analyst noted that a 6% price bump worldwide would be required to offset the damage.
Chinese consumer backlash against Nike intensified in May 2021 after the U.S. banned cotton imports linked to Xinjiang, causing Nike's growth in China to fall sharply from 38% to as low as -5% over the following quarters.
Although China now accounts for a smaller share of Nike's projected FY26 sales and profits than it did before the pandemic, the region remains critical.
Analysts project a continued downturn in Nike's China performance through the first half of FY26, following weaker margins and sales in FY25. While a rebound is anticipated in the second half, that outlook may be too hopeful if U.S.-China tensions persist.
Price Action: NKE shares traded lower by 1.90% at $57.37 at the last check on Friday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/25/04/45011895/the-future-of-flight-united-airlines-invests-in-radical-jet-design" target="_blank" rel="noreferrer noopener">The Future of Flight? United Airlines Invests In Radical Jet Design</a></li>
</ul>
Photo via Shutterstock

China Accounts Smaller Share In Nike Sales Compared To Pre-Pandemic Levels, But Tariff Pressure Still Persists: Analyst

PLTR

Palantir shares are trading higher. The stock has gained amid recent defense partnerships.

B of A Securities analyst Bryan D. Spillane on Friday, <a target="_blank" href="https://www.benzinga.com/quote/PG/analyst-ratings" rel="noreferrer noopener">reiterated a Buy rating</a> on Procter &amp; Gamble CO (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PG#NYSE">PG</a>) stock, and lowered the price forecast from $190.00 to $180.00.
PG's strong <a target="_blank" href="https://www.benzinga.com/25/04/44984872/gillette-parent-procter-gamble-slides-on-q3-sales-decline-lowered-outlook" rel="noreferrer noopener">third-quarter performance</a> was overshadowed by concerns over potential U.S. tariffs, which could cost the company $1 billion to $1.5 billion annually.
The analyst states that despite a 3.7% stock drop, PG believes it can offset the impact through favorable foreign exchange, lower input costs, and strategic pricing.
Also Read: <a target="_blank" href="https://www.benzinga.com/news/earnings/25/04/44977669/pepsico-ceo-warns-of-tariffs-led-increase-in-supply-chain-costs-cuts-annual-profit-outlook" rel="noreferrer noopener">PepsiCo CEO Warns Of Tariffs Led ‘Increase In Supply Chain Costs,' Cuts Annual Profit Outlook</a>
While category growth has softened slightly, core consumer demand remains stable. PG also reports positive momentum in China and Latin America.
Procter &amp; Gamble's reduced FY25 outlook reflects early tariff impacts and slower growth, but FY26 could see more upside if tariffs are eased and global consumer trends improve amid economic uncertainty.
The analyst has reduced the EPS projections for FY25 and FY26 due to expected margin compression. Fourth-quarter organic sales estimate has been slightly adjusted to a 1.9% increase based on flat volumes and 2% pricing growth.
The analyst has trimmed the fourth-quarter gross margin forecast by 30 basis points to 51.1%, down 10 basis points year-over-year, and cut EPS estimate by 9 cents to $1.44.
For FY25, the analyst has lowered gross margin expectations by 30 basis points to 51.6%, reflecting potential one-month tariff costs between $100 million and $160 million. The analyst has also reduced the sales and margin outlooks for FY26 and FY27 due to ongoing tariff pressures and slower category growth.
Price Action: PG shares traded higher by 1.04% at $161.16 at last check Friday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/25/04/45011895/the-future-of-flight-united-airlines-invests-in-radical-jet-design" target="_blank" rel="noreferrer noopener">The Future of Flight? United Airlines Invests In Radical Jet Design</a></li>
</ul>
Photo by Jonathan Weiss via Shutterstock

What Is The Tariff Risk For Procter & Gamble? Analyst Calculates, Trims Outlook

SMMT

Summit Therapeutics shares are trading lower. The company's partner Akeso received FDA approval for its PD-1 monoclonal antibody, penpulimab-kcqx, in combination with cisplatin or carboplatin and gemcitabine. The FDA also approved penpulimab-kcqx as a single agent.

As Nvidia (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) remains in the AI spotlight, Advanced Micro Devices Inc.&#8216;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMD#NASDAQ">AMD</a>) lesser valuation and increasing investor attention are making waves, particularly among smart-beta and <a href="https://www.benzinga.com/etfs">innovation-oriented funds</a>.
Here are three non-leveraged ETFs that include AMD:
<ul>
<li>ARK Autonomous Technology &amp; Robotics ETF (BATS:<a class="ticker" href="https://www.benzinga.com/stock/ARKQ#BATS">ARKQ</a>): Cathie Wood&#8216;s actively managed fund is doubling down on AMD, with <a href="https://www.benzinga.com/25/04/44969765/cathie-wood-buys-more-nvidia-and-amd-stock-as-chinese-tech-giants-stockpile-chips-amid-looming-us-export-curbs">consecutive buys of more than $2.3 million this week</a>. The fund price has returned 33% of value on the past year.</li>
</ul>
<ul>
<li>iShares Semiconductor ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SOXX#NASDAQ">SOXX</a>): With high concentration in chipmakers, SOXX is still holding a strong AMD allocation, wagering on secular growth in computing and AI infrastructure over the long term. The fund has had a price erosion of about 13% in the past year, but this fund might be a good long-term play: if you look at the price returns over the past 5 years, it is more than 139%.</li>
</ul>
<ul>
<li>VanEck Semiconductor ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMH#NASDAQ">SMH</a>): Another semiconductor ETF heavyweight, SMH has regularly had AMD as one of its top holdings, a testament to faith in the company&#8217;s capability to compete on price and performance. The past year has seen relatively flat prices.</li>
</ul>
Also Read: <a href="https://www.benzinga.com/etfs/specialty-etfs/25/04/44854262/chipwrecked-nvidias-export-ban-triggers-etf-meltdown-and-one-big-winner">Chipwrecked: Nvidia&#8217;s Export Ban Triggers ETF Meltdown (And One Big Winner)</a>
Since Nivida continues to trade in excess of 20 times last year&#8217;s revenues, <a href="https://www.benzinga.com/trading-ideas/long-ideas/25/04/45006075/sentiment-fissures-in-the-semiconductor-space-put-spotlight-on-direxions-amd-focused-bull-and-bear-funds">AMD&#8217;s more modest 6x revenue multiple </a>makes a relatively convincing case for portfolio diversification. It ain&#8217;t cheap-cheap, but in the chip business today, it&#8217;s almost torture to pass up.
Supporting the case for AMD is a bullish trend in the options market. On Thursday, Benzinga&#8217;s <a href="https://www.benzinga.com/insights/options/25/04/44990727/spotlight-on-advanced-micro-devices-analyzing-the-surge-in-options-activity">options scanner</a> caught a string of long-expiry call options on AMD — the traditional game played by institutions as a play for medium- to long-term conviction. 
Debit trades in this fashion don&#8217;t pay until and unless the stock reaches targets by expiration time, implying the speculators are not only positive but willing to put actual capital on it.
But optimism is asterisked. The U.S. government&#8217;s restrictions on AI chip exports to China, a key market, have placed a policy-induced cloud over the entire <a href="https://www.benzinga.com/topic/semiconductors">semiconductor industry</a>. 
Although former President Donald Trump has suggested a more relaxed approach, negotiations are tenuous. For AMD, that translates to surfing waves of hope and uncertainty in equal proportions.
But that hasn&#8217;t deterred contrarians or ETFs such as ARKQ from increasing their exposure. It is apparent now that AMD might not be the loudest name in the chip game, but it&#8217;s turning out to be one of the cleverest bets — and ETFs are taking notice.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/25/04/45014143/guidance-grounded-airline-stocks-shaky-as-carriers-bail-on-forecasts-etfs-enter-turbulence-zone">Airline Stocks Hit Headwinds As Carriers Cut Guidance, ETFs Enter Turbulence</a></li>
</ul>
Image: Shutterstock

ARKQ

NVDA

Forget Nvidia, ETFs Are Quietly Piling Into AMD — Do They Know Something We Don't?

April 25 (Reuters) - A U.S. judge has set a May 2 hearing to discuss remedies the U.S. Justice Department and a group of states might ask the court to impose on Google after it ruled the Alphabet <a href="https://workspace.refinitiv.com/web/apps/quotewebapi?RIC=GOOGL.O">GOOGL.O</a> unit illegally dominates two markets for online advertising technology.
In an order on Friday, U.S. District Judge Leonie Brinkema in the Alexandria, Virginia federal court set the hearing to get an early and broad sense from the Justice Department and states about the remedies that could be at issue, before embarking on a narrowly focused path.
The hearing will come after Brinkema in a <a href="reuters://REALTIME/verb=NewsStory/ric=nL1N3QV0M5">blockbuster order</a> on April 17 found Google liable for "willfully acquiring and maintaining monopoly power" in markets for publisher ad servers and the market for ad exchanges which sit between buyers and sellers.

Legal

GOOG

GOOGL

"A U.S. Judge Has Set A May 2 Hearing To Discuss Remedies The U.S. Justice Department And A Group Of States Might Ask The Court To Impose On Google After It Ruled The Alphabet Unit Illegally Dominates Two Markets For Online Advertising Technology" - Reuters News

HCA Healthcare shares are trading lower following Q1 earnings.

Trading Halt: Halt status updated at 3:15:00 PM ET: Quotation Resumption: News and Resumption Times

Summit Therapeutics Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMMT#NASDAQ">SMMT</a>) stock is trading lower on Friday.
On Thursday, Summit Therapeutics&#8217; partner Akeso Inc. received the U.S. Food and Drug Administration (FDA) approval for its PD-1 monoclonal antibody, penpulimab-kcqx, in combination with cisplatin or carboplatin and gemcitabine for the first-line treatment of adult recurrent or metastatic non-keratinizing <a target="_blank" href="https://www.benzinga.com/general/health-care" rel="noreferrer noopener">nasopharyngeal carcinoma (NPC)</a>.
FDA also <a target="_blank" href="https://www.prnewswire.com/news-releases/akeso-announces-fda-approval-for-penpulimab-kcqx-in-two-bla-indications-for-comprehensive-treatment-of-advanced-nasopharyngeal-carcinoma-302437965.html" rel="noreferrer noopener">approved</a> penpulimab-kcqx as a single agent for adults with metastatic non-keratinizing NPC with disease progression on or after platinum-based chemotherapy and with at least one other prior line of therapy.
Also Read: <a href="https://www.benzinga.com/general/biotech/25/03/44463128/analyst-initiates-coverage-on-undervalued-summit-therapeutics" target="_blank" rel="noreferrer noopener">Analyst Initiates Coverage On &#8216;Undervalued&#8217; Summit Therapeutics</a>
Penpulimab-kcqx was developed independently by Akeso, and further development and commercialization were managed through a joint venture with Chia Tai-Tianqing Pharmaceutical Group.
&#8220;This milestone marks penpulimab-kcqx as Akeso&#8217;s first internally developed innovative biologic to receive FDA approval&#8230;and marks Akeso&#8217;s successful entry into&nbsp;the United States&nbsp;regulatory system for the first time,&#8221; the company said in a press release on Thursday.
Penpulimab-kcqx has been approved in&nbsp;China&nbsp;for two indications:
<ul>
<li>First-line treatment of advanced NPC.</li>
<li>Second or later line treatment of advanced NPC.</li>
</ul>
The company added that the recent FDA approval of penpulimab-kcqx offers a new immunotherapy option for advanced NPC patients in the U.S.
The FDA approval is based on the international Phase 3 trial AK105-304 and the pivotal AK105-202 study, which supported the two Biologics License Application (BLA) for penpulimab-kcqx.
These studies demonstrated the drug&#8217;s clinical benefits and favorable safety profile across two stages of treatment for metastatic NPC.
Akeso and Summit Therapeutic are collaborating to develop ivonescimab, a PD-1/VEGF bispecific antibody.
On Wednesday, Akeso released topline data from the&nbsp;<a target="_blank" href="https://www.benzinga.com/general/biotech/25/04/44963467/why-is-summit-therapeutics-stock-soaring-on-wednesday" rel="noreferrer noopener">Phase 3 HARMONi-6/K112-306 trial</a>.
The trial evaluated Summit Therapeutic&#8217;s ivonescimab in combination with platinum-based chemotherapy, compared with tislelizumab, an anti-PD-1 antibody, in combination with platinum-based chemotherapy in patients with locally advanced or metastatic squamous non-small cell lung cancer (NSCLC),&nbsp;<a target="_blank" href="https://www.benzinga.com/pressreleases/25/04/b44944372/ivonescimab-in-combination-with-chemotherapy-achieves-statistically-significant-superiority-in-pfs" rel="noreferrer noopener">irrespective of PD-L1 expression</a>.
The trial met its primary endpoint of progression-free survival (PFS).
In September 2024, Summit Therapeutics&nbsp;released data from the primary analysis of the Phase 3 HARMONi-2 trial of ivonescimab&nbsp;<a target="_blank" href="https://www.benzinga.com/analyst-ratings/analyst-color/24/11/41724651/summit-therapeutics-unique-investment-in-oncology-lead-drug-candidate-shows-promise" rel="noreferrer noopener">conducted in China</a>.
Ivonescimab monotherapy demonstrated a statistically significant improvement in the trial&#8217;s primary endpoint, progression-free survival, compared to monotherapy Merck &amp; Co Inc&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRK#NYSE">MRK</a>) Keytruda (pembrolizumab), achieving a&nbsp;<a target="_blank" href="https://www.benzinga.com/general/biotech/24/09/40771038/summit-therapeutics-lung-cancer-candidate-surpasses-mercks-multi-billion-dollar-keytruda-cuts-ris" rel="noreferrer noopener">hazard ratio (HR) of 0.51</a>.
On Friday, China&#8217;s National Medical Products Administration <a target="_blank" href="https://www.prnewswire.com/news-releases/ivonescimab-receives-nmpa-approval-for-first-line-treatment-of-pd-l1-positive-nsclc-based-on-breakthrough-head-to-head-phase-iii-trial-demonstrating-superior-efficacy-over-pembrolizumab-302438600.html" rel="noreferrer noopener">approved</a> supplemental application for ivonescimab for use as a monotherapy for the first-line treatment of PD-L1-positive (TPS ≥ 1%) non-small cell lung cancer (NSCLC) in patients who are negative for epidermal growth factor receptor (EGFR) gene mutations and anaplastic lymphoma kinase (ALK) gene mutations.
This indication marks Ivonescimab&#8217;s second major approval.
Price Action: SMMT stock is down 36.8% at $23.21 at the last check Friday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/04/45012329/amazon-sellers-hike-prices-on-essentials-as-trumps-china-tariffs-squeeze-margins" target="_blank" rel="noreferrer noopener">Amazon Sellers Hike Prices On Essentials As Trump China Tariffs Squeeze Margins</a></li>
</ul>

Health Care

Movers

What's Going On With Summit Therapeutics Stock On Friday?

Cryptocurrency markets are trading higher as whales continue an accumulation spree to fuel bullish momentum.
<figure class="wp-block-table"> 
<table>
<tbody>
<tr>
<td>Cryptocurrency</td>
<td>Price&nbsp;&nbsp;&nbsp;</td>
<td>Gains +/-</td>
</tr>
<tr>
<td>Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>)</td>
<td>$95,277.12</td>
<td>+2%</td>
</tr>
<tr>
<td>Ethereum (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/eth/usd">ETH</a>)</td>
<td>$1,799.22</td>
<td>+2.2%</td>
</tr>
<tr>
<td>Solana (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/sol/usd">SOL</a>)</td>
<td>$151.53</td>
<td>-0.2%</td>
</tr>
<tr>
<td>XRP (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/xrp/usd">XRP</a>)</td>
<td>$2.19</td>
<td>-0.4%</td>
</tr>
<tr>
<td>Dogecoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/doge/usd">DOGE</a>)</td>
<td>$0.1815</td>
<td>+0.6%</td>
</tr>
<tr>
<td>Shiba Inu (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/shib/usd">SHIB</a>)</td>
<td>$0.00001387</td>
<td>+2.7%</td>
</tr>
</tbody>
</table>
</figure>
Notable Statistics:
<ul>
<li>IntoTheBlock data shows large transaction volume decreasing by 22.1% and daily active addresses growing by 7.8%. Transactions greater than $100,000 are down from 11,905 to 10,849 in a single day. Exchanges netflows are down by 5,813.9%.</li>
<li>Coinglass data reports 131,279 traders were liquidated in the past 24 hours for $291.56 million.</li>
<li>Crypto chart analyst Ali Martinez <a href="https://x.com/ali_charts/status/1915542519724511667">noted</a> that Bitcoin miners have earned more than $18.57 million in profits as prices raced ahead above $93,000.</li>
</ul>
Notable Developments:
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/25/04/45007049/bitcoin-etfs-see-442m-daily-inflow-as-btc-hovers-around-94000">Bitcoin ETFs See $442M Daily Inflow As BTC Hovers Around $94,000</a></li>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/25/04/45008113/bitcoin-fundamentally-decoupled-from-us-tech-stocks-blackrocks-jay-jacobs-says">Bitcoin Fundamentally Decoupled From US Tech Stocks, BlackRock&#8217;s Jay Jacobs Says</a></li>
<li><a href="https://www.benzinga.com/personal-finance/25/04/45014801/heres-why-bitcoin-has-decoupled-from-stocks-according-to-standard-chartered">Here&#8217;s Why Bitcoin Has Decoupled From Stocks According To Standard Chartered</a></li>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/25/04/45001061/shaq-agrees-to-amicable-proposed-resolution-with-ftx-investors-terms-to-remain-confidential">Shaq Agrees To &#8216;Amicable Proposed Resolution&#8217; With FTX Investors, Terms To Remain Confidential</a></li>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/25/04/45012922/trump-meme-coin-surges-15-as-organizers-clarify-participation-rules-for-gala-dinner">TRUMP Meme Coin Surges 15% As Organizers Clarify Participation Rules For Gala Dinner</a></li>
</ul>
Top Gainers:
<figure class="wp-block-table"> 
<table>
<tbody>
<tr>
<td>Cryptocurrency</td>
<td>Price&nbsp;&nbsp;&nbsp;</td>
<td>Gains +/-</td>
</tr>
<tr>
<td>Bitcoin SV (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/">BSV</a>)</td>
<td>&nbsp;$45.31</td>
<td>+47.7%</td>
</tr>
<tr>
<td>Virtuals Protocol (CRYPTO: VIRTUAL)</td>
<td>&nbsp;$0.9258</td>
<td>+24.8%</td>
</tr>
<tr>
<td>Dogwifhat (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/">WIF</a>)</td>
<td>&nbsp;$0.6327</td>
<td>+16.3%</td>
</tr>
</tbody>
</table>
</figure>
Trader Notes: Crypto chart trader Jelle observed that Bitcoin surged straight into the $90,000–$94,000 range with no real pause. 
If BTC manages to hold this zone through the end of the day, he expects weekend volatility, but believes the uptrend could carry into next week, citing strong bullish momentum.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true"><a href="https://twitter.com/hashtag/Bitcoin?src=hash&amp;ref_src=twsrc%5Etfw">#Bitcoin</a> just chadded straight to the $90-94k area without stopping &#x1f440; Hold it above there until end of business today, let the weekend be choppy and we can resume pushing higher next week. Good stuff, happy weekend! <a href="https://t.co/EpYnVe81CT">https://t.co/EpYnVe81CT</a> <a href="https://t.co/6eSZnQjlBI">pic.twitter.com/6eSZnQjlBI</a>
&mdash; Jelle (@CryptoJelleNL) <a href="https://twitter.com/CryptoJelleNL/status/1915780726542229602?ref_src=twsrc%5Etfw">April 25, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Trader Degen Hardy is <a href="https://x.com/Degen_Hardy/status/1915770342267846735">watching</a> the $86,000–$88,000 zone as a possible long entry, noting it likely aligns with previous structural support or a key moving average. 
He warns that a weekend dip to shake out weak hands is possible given thinner liquidity. 
That said, if bulls maintain control, Bitcoin might either front-run the dip or simply continue grinding higher.
Elsewhere, Titan of Crypto <a href="https://x.com/Washigorira/status/1915793345852457242">noted</a> that Bitcoin has hit the $95,000 target and now eyes $99,000 as the next key resistance. 
However, he emphasizes the importance of holding above the prior monthly high, which BTC has just tapped, to confirm continued strength.
Read Next:&nbsp;
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/25/04/45017648/bitcoin-climbs-12-on-the-week-as-traders-eye-run-to-100000">Bitcoin Climbs 12% On The Week As Traders Eye Run To $100,000</a></li>
</ul>

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$BSV

$BTC

$DOGE

$ETH

$SHIB

$SOL

$WIF

$XRP

Bitcoin, Ethereum, XRP, Dogecoin Surging, But 'Choppy' Weekend Could Precede The Next Push

Fermium Research analyst Frank J. Mitsch upgraded Dow Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DOW#NYSE">DOW</a>) from Hold to Buy <a target="_blank" href="https://www.benzinga.com/quote/DOW/analyst-ratings" rel="noreferrer noopener">at a price forecast of $35</a>.
On Thursday, the company reported better-than-expected&nbsp;first-quarter 2025 sales of $10.431 billion, beating the consensus of $10.24 billion, and adjusted EPS of $0.02, beating the <a target="_blank" href="https://www.benzinga.com/25/04/44978321/dow-posts-surprise-profit-as-volumes-rise-in-q1-but-cash-flow-and-capex-outlook-signal-market-caution" rel="noreferrer noopener">consensus estimate of a $0.01 loss</a>.
The analyst views Dow&#8217;s decision to postpone the Ft. Saskatchewan Path2Zero project, which is expected to yield an additional $600 million in capex savings in 2025, as a significant positive.
Also Read: <a target="_blank" href="https://www.benzinga.com/25/04/44824289/dow-downgraded-analyst-sees-dividend-risk-trade-war-concerns-a-major-headwind" rel="noreferrer noopener">Dow Downgraded: Analyst Blames &#8216;Perfect Storm&#8217; Of Weak Macro, High Costs, Trade Barriers</a>
Mitsch believes that this, coupled with the Macquarie infrastructure sale(s) and anticipated NOVA litigation proceeds, should ease dividend concerns for 2025 and 2026.
Nevertheless, the anticipated negative free cash flow of up to $1 billion in the first half of 2025 is a point of concern, adds the analyst.
The analyst anticipates a reversal in the second half, driven by working capital inflows, reduced maintenance spending, and increased EBITDA from new projects and cost reductions.
Amid the continued weak macroeconomics, the analyst lowered 2025 EPS estimates from $1.61 to $0.29 (consensus $1.40) and EBITDA estimates from $5.20 billion to $4.05 billion (consensus $4.82 billion).
Also, Mitsch cuts second-quarter EPS and EBITDA estimates from $0.48 and $1.39 billion to $0.00 and $960 million (vs. consensus of $0.33 and $1.25 billion), respectively.
Investors can gain exposure to the stock via Materials Select Sector SPDR (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLB#NYSE">XLB</a>) and Invesco S&amp;P 500 High Dividend Low Volatility ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPHD#NYSE">SPHD</a>).
Price Action: DOW shares are up 0.37% at $29.87 at the last check Friday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com//node/44994357" target="_blank" rel="noreferrer noopener">Orion Stock Has Limited Upside Amid Uncertain Economic Backdrop: JP Morgan</a></li>
</ul>
Photo via Shutterstock

Upgrades

SPHD

Analyst Upgrades Dow, Calls Capex Cut And Asset Sales Positive

WW International shares are trading higher after Galloway Capital Partners disclosed a 2.87% stake in the company and said a Chapter 11 filing 'would make little sense.'

Markets momentarily flipped southward on Friday after President Donald Trump said he would maintain tariffs on China unless <a href="https://www.benzinga.com/topic/donald-trump">substantial concessions were made. </a>
Speaking aboard Air Force One on his way to Rome for Pope Francis&#8217; funeral, Trump said he would not ease tariffs without &#8220;something substantial&#8221; from China, stressing the need to &#8220;open China&#8221; for American businesses. 
&#8220;We almost got it and then they backed out of that deal,&#8221; he said, adding that Chinese officials &#8220;don&#8217;t want it open&#8221; but that opening the Chinese market would be a &#8220;big win.&#8221;
Tariffs, Trump said, are key to restoring U.S. economic strength. 
&#8220;Because of tariffs, I could possibly get that,&#8221; he said. &#8220;We&#8217;re going to make—we&#8217;ll be making five billion a day,&#8221; adding that the U.S. had been losing billions daily under previous administrations.
&#8220;We&#8217;ll be reasonable, very reasonable,&#8221; Trump said. 
&#8220;We set the price.&#8221; 
Responding to questions about whether markets were adjusting to tariffs, Trump said he believed they were, adding, "I said there'd be a transition. People haven't understood it. Now they're starting to understand."
<h3 class="wp-block-heading">Stocks Retreat After Rally</h3>
Markets reacted swiftly to Trump&#8217;s comments. The S&amp;P 500 – as tracked by the SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) – fell 0.6% in reaction to Trump&#8217;s comments, before quickly recovering.
The Dow Jones Industrial Average shed 200 points, dropping to 39,933 by 2:00 p.m. ET, while the Nasdaq 100 retreated from 19,500 to 19,290, before both bounced back.
In the initial reaction to Trump&#8217;s remarks, Coinbase Global Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COIN#NASDAQ">COIN</a>) lost 1.8%, Shopify Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SHOP#NYSE">SHOP</a>) declined 1.7% and Nvidia Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) fell 1.4%, while Tesla Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>), slipped 1.3%, according to <a href="https://www.benzinga.com/pro/?utm_source=BZprocontent&amp;t=be2bearmibe3na1">Benzinga Pro</a> platform.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/analyst-color/25/04/45007990/stay-big-sell-rips-hartnett-doubts-bull-market-without-3-key-catalysts">&#8216;Stay BIG, Sell Rips&#8217;: Hartnett Doubts Bull Market Without 3 Key Catalysts</a></li>
</ul>
Photo: noamgalai/Shutterstock

Government

Regulations

COIN

SHOP

TSLA

Markets Wobble As Trump Rejects Dropping China Tariffs Without Deal

Ohio Valley Banc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OVBC#NASDAQ">OVBC</a>) reported quarterly earnings of $0.94 per share. This is a 62.07 percent increase over earnings of $0.58 per share from the same period last year.

OVBC

Ohio Valley Banc Q1 EPS $0.94 Up From $0.58 YoY

Press Releases

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Biohaven Ltd - BHVN

Biohaven Presents Data Across Innovative Neuroscience Portfolio at the 2025 American Academy of Neurology (AAN) Annual Meeting

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Biohaven Ltd. - BHVN

Small Cap

BHVN Investors Have Opportunity to Join Biohaven Ltd. Fraud Investigation with the Schall Law Firm

BHVN

Ascentage Pharma Group International - American Depository Shares

Ascentage Pharma Group

ACADIA Pharmaceuticals Inc. - Common Stock

ACADIA Pharmaceuticals

Akero Therapeutics

Alvotech

Apogee Therapeutics

Apellis Pharmaceuticals, Inc. - Common Stock

Apellis Pharmaceuticals

Beam Therapeutics

Catalyst Pharmaceuticals, Inc. - Common Stock

Catalyst Pharmaceuticals

Crinetics Pharmaceuticals, Inc. - Common Stock

Crinetics Pharmaceuticals

Denali Therapeutics

Amicus Therapeutics

ImmunityBio

Immunovant

Kymera Therapeutics

Mirum Pharmaceuticals, Inc. - common stock

Mirum Pharmaceuticals

MoonLake Immunotherapeutics - Class A Ordinary Shares

MoonLake

Metsera

NewAmsterdam Pharma Company N.V. - Ordinary Shares

NewAmsterdam Pharma Co

Protagonist Therapeutics, Inc. - Common Stock

Protagonist Therapeutics

Recursion Pharmaceuticals, Inc. - Class A Common Stock

Recursion Pharmaceuticals

Scholar Rock Holding Corporation - Common Stock

Scholar Rock Holding

Twist Bioscience Corporation - Common Stock

Comments

Biohaven

Noticias

Últimas noticias sobre Biohaven (NYSE:BHVN) Bolsa

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL